Summary The present report describes the non-haematological toxicity and the influence of growth factor administration on haematological toxicity and haematopoietic recovery observed after high-dose carboplatin (1200 mg m-2), etoposide (900 mg m-2) and melphalan (100 mg m-2) (CEM) followed by peripheral blood progenitor cell transplantation (PBPCT) in 40 patients with high-risk cancer during their first-line treatment. PBPCs were collected during the previous outpatient induction chemotherapy programme by leukaphereses. CEM administration with PBPCT was associated with low non-haematological toxicity and the only significant toxicity consisted of a reversible grade III/IV increase in liver enzymes in 32% of the patients. Haematopoietic recovery was very fast in all patients and the administration of granulocyte colony-stimulating factor (G-CSF) plus erythropoietin (EPO) or granulocyte-macrophage colony-stimulating factor (GM-CSF) plus EPO after PBPCT significantly reduced haematological toxicity, abrogated antibiotic administration during neutropenia and significantly reduced hospital stay and patient's hospital charge compared with patients treated with PBPCT only. None of the patients died early of CEM plus PBPCTrelated complications. Low non-haematological toxicity and accelerated haematopoietic recovery renders CEM with PBPC/growth factor support an acceptable therapeutic approach in an adjuvant or neoadjuvant setting.
High-dose chemotherapy (HDC) with autologous haematopoietic progenitor support is a promising approach for increasing the dose intensity of first-line treatment in patients with high-risk cancer who respond to conventional therapy (McMillan et al, 1991; Peters et al, 1993a; Wheeler et al, 1993; Ayash et al, 1994; Gianni et al, 1994; Benedetti Panici et al, 1995) . Unfortunately, HDC is limited by significant morbidity and mortality related to haematological and non-haematological toxicities. Hence, the development of novel intensive treatment programmes with acceptable toxicity is required to clarify the role of high-dose polychemotherapy during the initial treatment of high-risk cancer. The use of carboplatin (CBDCA) with haematopoietic progenitor cell support in the intensification phase has been suggested in patients suffering from several solid tumours. CBDCA shows a similar activity to cisplatin (CDDP) (Ozols et al, 1985) , but it causes less nausea and vomiting and less neurotoxicity, its dose-limiting toxicity being myelosuppression. In fact, the lack of non-haematological toxicity makes CBDCA a potentially useful drug in a high-dose chemotherapy setting, when recovery from myelosuppression can be accomplished by the use of adequate haematological support. Etoposide (VP16) is a semi-synthetic derivative of podophyllotoxin with significant cytotoxic activity in a broad spectrum of human tumours, including small-cell lung cancer, testicular cancer, lymphoma, ovarian cancer, breast cancer and paediatric tumours (Aisner and Lee, 1991) . A relevant characteristic of VP16 is its low non-haematological toxicity. VP16 may be combined with CBDCA because it shows synergistic activity both in vivo and in vitro with platinum compounds (Schabel et al, 1979; Loehrer et al, 1986) , and the combination has produced responses in recurrent childhood tumours (Castello et al, 1990) . Melphalan (L-PAM) is one of the most effective single alkylating chemotherapeutic agents against epithelial ovarian carcinoma (Piver, 1984) and shows a steep dose-response curve in breast carcinoma in vitro and in vivo (Vincent et al, 1988; Ayash et al, 1991) . The effectiveness of this drug is dose dependent and it shows a prominent haematological toxicity. Each of the three above-mentioned agents exerts a different cell cycle-specific activity and they do not have significant or overlapping non-haematological toxicities. The present report describes the non-haematological toxicity and the influence of growth factor administration on haematological toxicity and haematopoietic recovery observed after high-dose CBDCA, VP16 and L-PAM (CEM) followed by the infusion of haematopoietic progenitor cells in patients with high-risk cancer. CEM was administered as a consolidation therapy during the first-line treatment of 26 patients with ovarian cancer (OvCa) and 14 patients with breast cancer (BrCa) and it was followed by peripheral blood progenitor cell transplantation (PBPCT) with or without post-PBPCT growth factor administration.
PATIENTS AND METHODS Patients
From June 1993 to December 1995, 24 patients with stage III or IV ovarian carcinoma (OvCa) with a residual tumour < 1 cm after cytoreductive or intervention cytoreductive surgery and 14 patients with stage II or III resectable breast cancer (BrCa) with eight or more involved axillary lymph nodes, ranging in age from 35 to 60 years (median 48 years), were enrolled in this phase I/II study (Table 1 ). All patients were previously untreated with chemotherapy or radiotherapy. Eligibility criteria included a performance status of 0-2 (WHO scale), adequate pulmonary, cardiac, hepatic and renal function, absence of underlying infections, a polymorphonuclear leucocyte count > 2 x 109 1-' and a platelet count > 100 x 109 1-'. The study was approved by the Hospital Human Investigation Review Board and written informed consent was obtained from all patients.
Treatment plan
All patients were treated with an outpatient chemotherapy induction programme followed by high-dose chemotherapy consolidation with CEM, followed by the reinfusion of peripheral blood progenitor cells (PBPCs) collected after low-dose cyclophosphamide (LDCy) plus recombinant human G-CSF (rhG-CSF) in combination with cisplatin (CDDP) . Collections were started on day 12 after LD-Cy plus rhG-CSF in combination with CDDP or EPR and performed on consecutive days until a minimum of 4 x 108 kg-' peripheral blood mononuclear cells were collected per patient, as previously described . All patients with OvCa were treated with three additional courses of conventional dose 600 mg m-2Cy on day 1 and 100 mg m-2 CDDP on day 1, administered every 15 days, after the administration of LD-Cy + CDDP. After the administration of LDCy + EPR, all patients with BrCa were treated with four additional courses of conventional-dose 600 mg mi-2 Cy on day 1 and 120 mg m-2EPR on day 1, administered every 15 days. In all patients, CEM consisted of the administration of cumulative doses of 1200 mg m-2 CBDCA, 900 mg n-2 VP16 and 100 mg m-2 L-PAM from day -4 to day -1. On day 0, PBPCs were reinfused into the patients, immediately after thawing, through a central venous catheter. The infusion of the whole graft was completed within a period of 24 h in all cases. Ten consecutive patients (group A) did not receive haematopoietic growth factor following PBPCT. Fifteen consecutive patients (group B) were treated 24 h after the infusion of PBPCs with rhG-CSF (Neupogen) at a dose of 5 ,ug kg-' subcutaneously (s.c.) every 24 h until day + 12 and with recombinant human erythropoietin (rhEPO; Globuren, Dompe Biotec, Milan, Italy) at a dose of 150 IU kg-' s.c. every 48 h until day + 11. Twenty-four hours after the infusion of PBPCs, 15 consecutive patients (group C) received recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; Mielogen Schering Plough, Milan, Italy) at a dose of 5 gg kg-' s.c. every 24 h until day + 12 and rhEPO (Globuren) at a dose of 150 IU kg-' s.c. every 48 h until day + 11. All patients were nursed in conventional single-bed rooms and access to patients' rooms required masks, gloves, gowns and shoe covers. Patients received PBPCT, peripheral blood progenitor cell transplantation; G-CSF, granulocyte colony-stimulating factor; EPO, erythropoietin; GM-CSF, granulocyte-macrophage colony-stimulating factor; RBC, red blood cells; PLT, platelets. Results are presented as the median value (range). aComparisons were made by Kruskal-Wallis and Mann-Whitney U non-parametric tests.
parenteral hyperalimentation from HDC to complete haematopoietic recovery. Antimicrobial and antifungal prophylaxis consisted of the daily administration of ciprofloxacin (1000 mg day-'), fluconazole (150 mg day-'), acyclovir (800 mg day-') and trimethoprim/sulphamethoxazole (960 mg day-') twice a week from CEM to day + 40. During the period of neutropenia, patients were started immediately on broad-spectrum antibiotics when they had a sustained fever of > 38°C for more than 12 h and amphotericin B was added when fever persisted for more than 7 days in spite of antibiotic treatment. 
Statistical analysis
Comparisons between groups of patients were performed by the Kruskal-Wallis and Mann-Whitney U non-parametric tests. A P-value < 0.05 was considered significant. Influence of growth factor administration on haematological toxicity and haematopoietic recovery
As detailed in Patients and methods, haematopoietic support consisted of PBPC infusion alone in ten patients (group A), PBPC infusion and G-CSF plus EPO administration in 15 patients (group B) and PBPC infusion and GM-CSF plus EPO administration in 15 patients (group C) (Tables 3 and 4). All groups of patients were balanced with respect to age, CFU-GM kg-1 and MNC kg-' infused doses. After the administration of CEM combination, severe myelosuppression occurred in all patients. All groups of patients we studied recovered promptly from myelosuppression, but group B achieved PMN > 0.5 x 109 1-1 and WBC > 1 x 109 1-1 significantly earlier than groups A and C (Table 3) . Additionally, group B recovered 50 x 109 1-' PLTs significantly faster than group C and faster than group A with a borderline significance (Table 3 ). In the same way, the number of days with PMN < 0.2 x 109 1-1 and PMN < 0.5 x 109 1-1 were significantly lower for group B compared with group A (Table 3) . Conversely, the number of days with WBC < 1
x 109 1-' were significantly lower for groups B and C compared with group A (Table 3) . Group B patients required a lower number of single-donor PLT transfusions with borderline significance compared with group A (Table 4) . Most of the patients did not require RBC transfusions (Table 4 ). Figure 1 details the kinetics of haematopoietic reconstitution of each patient group.
Fever and infection
Eighty per cent of the patients in group A and 90% of the patients in group C developed fever. None of the patients in group B had fever. A microbiologically documented infection was observed in only one patient in group A (Candida glabrata). Fever episodes required systemic antibiotic treatment in all group A patients, while the intermittence of fever episodes in group C discouraged the use of systemic antibiotics. As a consequence, in group B and C patients systemic antibiotics were not administered (Table 4) .
Hospital stay
Group B and C patients were discharged from the hospital after a significantly shorter period of time than group A patients (Table  4 ). The median hospital stay (including the period required for CEM administration) for group A patients was 20 days (range 18-38), for group B it was 18 days (range 14-22) and for group C it was 16 days (range 13-22).
Survival
None of the patients treated with CEM and PBPCT died within 100 days after transplant of transplant-related complications. At the present time, 32 patients (80%) are alive without evidence of disease, with a median follow-up of 22 months (range 4-44) six patients (15%) are alive with recurrent disease or residual disease with a median follow-up of 20 months (range 15-34) and two patients (5%) have died of recurrent disease. None of the patients experienced long-term complications related to the transplant procedure and all living patients show sustained haematopoiesis. All patients with residual or recurrent disease underwent secondline treatment and showed mild and predictable haematological and non-haematological toxicities.
DISCUSSION
The present report describes the non-haematological toxicity and the influence of growth factor administration on haematological toxicity and haematopoietic recovery observed after high-dose CEM with PBPCT in patients with high-risk ovarian or breast British Journal of Cancer (1997) 75(8) figure; group B in the text) and 15 patients with granulocyte-macrophage colony-stimulating factor + erythropoietin combination (PBPCT + GM-CSF + EPO in the figure; group C in the text). The average blood counts following PBPCT (day 0) observed in the patients included in the different groups have been plotted and compared. WBC, white blood cells; PMN, polymorphonuclear leucocytes; PLT, platelets; Hb, haemoglobin cancer who underwent late intensification during their first-line treatment. A mild to moderate non-haematological toxicity was observed in most patients after CEM and PBPCT, and none of the patients had severe organ toxicities that discouraged the treatment of additional patients. CEM administration did not cause any cardiac, renal or bladder toxicities and a grade IV increase in serum transaminases was observed in only 12% of the patients. Grade II nausea and vomiting (observed in about 60% of the patients) and grade 11I enteritis (observed in about 80% of the patients) were the clinically relevant non-haematological toxicities of this high-dose treatment. In terms of non-haematological toxicity, these results are similar to or better than those reported elsewhere for other combinations of high-dose alkylating agents with progenitor cell support in combination or not with etoposide (Williams et al, 1987; Gaspard et al, 1988; Slease et al, 1988; Vincent et al, 1988; Eder et al, 1990; Elias et al, 1991; Williams et al, 1992; Siegert et al, 1994; Benedetti Panici et al, 1995) . Our results are better in terms of non-haematological toxicity than those reported recently for patients with high-risk cancer treated with ifosfamide, carboplatin and etoposide (Barnett et al, 1993; Fields et al, 1994; Elias et al, 1995) , high-dose cyclophosphamide and etoposide (de Graaf et al, 1994) , high-dose cyclophosphamide and carboplatin (Spitzer et al, 1995) , the quality of the graft collected in these patients, most of whom were chemotherapy-naive at the time of PBPC mobilization and collection, made it possible to obtain an accelerated haematopoietic recovery in most patients, faster than that reported in several other experiences of PBPC transplantation (Gianni et al, 1989; Menichella et al, 1991; Elias et al, 1992; To et al, 1992; Henon et al, 1992; Sheridan et al, 1992; Peters et al, 1993b; Sica et al, 1993; Chao et al, 1993; Bensinger et al, 1993; Pierelli et al, 1994; Spitzer et al, 1994; Shimazaki et al, 1994; Bishop et al, 1994) . The present study also shows that a significantly faster WBC, PMN and PLT recovery can be achieved by administering G-CSF plus EPO after PBPCT, as described previously (Pierelli et al, 1996) . On the other hand, a significant decrease in the number of days with WBC < 1 x 109 1-' can be obtained by administering either G-CSF plus EPO or GM-CSF plus EPO after PBPCT. In fact, the main advantage of administering G-CSF plus EPO is a more rapid recovery of mature granulocytes, while in GM-CSF plus EPO-treated patients the persistence of an immature leucocyte population was observed by us in the first days of recovery. Most of the patients did not require RBC transfusion and patients treated with growth factors after PBPCT had a less marked decline of Hb levels than patients treated with PBPCT only (Figure 1 ). The administration of EPO with G-CSF and GM-CSF after PBPCT probably abrogated the previously described detrimental effect of G-CSF and GM-CSF on PLT recovery after PBPCT (Spitzer et al, 1994; Shimazaki et al, 1994; Bensinger et al, 1994) , which could be caused by a prevalent potentiation of myelopoiesis with a consensual progenitor cell competition in vivo. Patients treated with growth factors did not require systemic antibiotic therapy with the total abrogation of neutropenic fever in G-CSF plus EPO-treated patients, while GM-CSF plus EPO-treated patients experienced only episodes of intermittent hyperthermia, which did not meet the criteria for the start of systemic antibiotic treatment. Only one patient in the present study experienced a microbiologically documented infection (Candida glabrata) and she belonged to the group of patients treated with PBPCs only. The reduction of haematological toxicity in our series and particularly in G-CSF plus EPO-and GM-CSF plus EPO-treated patients translated into a global simplification of the patients' clinical management with a significant reduction of hospital stay compared with several other studies on PBPCT (Gianni et al, 1989; Menichella et al, 1991; Elias et al, 1992; Henon et al, 1992; Sheridan et al, 1992; To et al, 1992; Bensinger et al, 1993; Chao et al, 1993; Peters et al, 1993b; Sica et al, 1993; Pierelli et al, 1994; Shimazaki et al, 1994; Spitzer et al, 1994; Bishop et al, 1994) . None of the patients died early of CEM plus PBPCT-related complications and this is one of the best results reported in high-dose treatment with haematopoietic support. None of the patients experienced long-term complications related to the transplant procedure and those patients who underwent second-line treatment for residual or recurrent disease (six patients with ovarian cancer) showed mild and predictable haematological and non-haematological toxicities. The median hospital charge for a patient treated with PBPCT only was £13 500, while it was £12 000 (this charge includes the cost of cytokine administration in both G-CSF plus EPO-and GM-CSF plus EPO-treated patients) for a patient treated with growth factors after PBPCT. Finally, this study shows that CEM with PBPCT plus growth factor administration is a very safe approach for delivering chemotherapy intensification to patients with high-risk cancer during their first-line treatment. Low non-haematological toxicity and accelerated haematopoietic recovery render CEM with PBPC/growth factor support an acceptable therapeutic approach in an adjuvant or neoadjuvant setting. No relevant differences were observed between patients treated with G-CSF plus EPO and patients treated with GM-CSF plus EPO in terms of clinical management. Studies are now in progress to verify which growth factor combination produces the best immunological reconstitution following CEM and PBPCT.
